The neuropharmacology of (-)-Stepholidine and its potential applications

Kechun Yang, Guozhang Jin, Jie Wu

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) DI partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinson's disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalCurrent Neuropharmacology
Issue number4
StatePublished - Dec 2007
Externally publishedYes


  • Dopamine D1 receptor
  • Dopamine D2 receptor
  • Parkinson's disease
  • Schizophrenia
  • Stepholidine

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'The neuropharmacology of (-)-Stepholidine and its potential applications'. Together they form a unique fingerprint.

Cite this